retatrutide dosing study latest trial results clinical trials phase approval: FDA status, results, and when it could be available Do not obsess over Retatrutide. – Phase III retatrutide demonstrates – retatrutide trial dose clinical dosing

BPC-157 + TB-500 + GHK-Cu Stack No published human or animal trial of all three together

and say, please, please, we have an obligation, says Volkow

Limited Long-Term Data Mounjaro only approved in 2022 Zepbound only approved in 2023 Long-term safety profile still emerging Unknown effects of decades-long use 2

Check with your clinician before starting them

The Study: Real-World Weight Loss Outcomes Researchers analyzed data from over 50,000 adults with obesity: 38,545 patients received a GLP-1 medication such as semaglutide or tirzepatide 12,540 patients underwent bariatric surgery, primarily gastric bypass or sleeve gastrectomy Key Findings : Surgery patients lost an average of 24% of their body weight over two years about 58 pounds

Disturbances in AMPK signaling and overall energy balance lead to chronic inflammation, obesity, and the development of age-related diseases (Lee 2013